Nasdaq IPOs

iTeos Therapeutics, a Phase 1/2 oncology biotech, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering. The company's lead candidate EOS-850, a highly selective small molecule antagonist of the adenosine A2a receptor (A2AR), is in an

Relay Therapeutics, a Phase 1 biotech developing small molecule therapies for solid tumors, filed on Wednesday with the SEC to raise up to $200 million in an initial public offering. The company's lead candidate RLY-1971, an inhibitor of Src homology region 2 domain-containing ph

Fusion Pharmaceuticals, a Phase 1 biotech developing precision medicines for solid tumors, raised the proposed deal size for its upcoming IPO on Wednesday. The Hamilton, Canada-based company now plans to raise $188 million by offering 12.5 million shares at a price range of $14 t

Fusion Pharmaceuticals, a Phase 1 biotech developing precision medicines for solid tumors, raised the proposed deal size for its upcoming IPO on Wednesday. The Hamilton, Canada-based company now plans to raise $188 million by offering 12.5 million shares at a price range of $14 t

The fourth-largest grocer in the US, Albertsons Companies (ACI) serves over 33 million customers per week through its 2,260 grocery stores. It operates under banners Albertsons, Safeway, Vons, Pavilions, Randalls, Tom Thumb, Carrs, Jewel-Osco, Acme, Shaw’s, Star Market, Uni

Dun & Bradstreet Holdings, which provides commercial data analytics services, announced terms for its IPO on Wednesday. In its latest filing, the company also added 16 underwriters. The Short Hills, NJ-based company plans to raise $1.3 billion by offering 65.8 million shares

Accolade, which provides a healthcare benefits management platform for self-insured employers, announced terms for its IPO on Wednesday. The Plymouth Meeting, PA-based company plans to raise $175 million by offering 8.8 million shares at a price range of $19 to $21. At the midpoi

Brilliant Acquisition, a blank check company targeting an Asia Pacific business, raised $40 million by offering 4 million units at $10. Each unit consists of one share of common stock, one warrant exercisable at $11.50, and one right to receive one-tenth a share of common stock.

Greenwich LifeSciences, a Phase 3 biotech developing immunotherapies for breast cancer, announced terms for its IPO on Tuesday. The Stafford, TX-based company plans to raise $21 million by offering 2.7 million shares (63% insider) at a price range of $7.50 to $8.50. At the midpoi

Pershing Square Tontine Holdings, a blank check company formed by Bill Ackman of Pershing Square targeting "Mature Unicorns," filed on Monday with the SEC to raise up to $3 billion in an initial public offering, which would make it the largest SPAC ever. To screen for upcoming or

Pershing Square Tontine Holdings, a blank check company formed by Pershing Square targeting "Mature Unicorns," filed on Monday with the SEC to raise up to $3 billion in an initial public offering, making it the largest SPAC ever. The company plans to raise an additional $1 billio

ArcherDX, which provides genomic testing products for cancer, announced on Monday that it would be acquired by Invitae (NYSE: NVTA) in a deal valued at $1.4 billion. ArcherDX originally filed for an IPO earlier this month with a proposed deal size of $100 million. The $1.4 billio

nCino, which offers cloud-based software for financial institutions, filed on Monday with the SEC to raise up to $100 million in an initial public offering. With fundamental elements built on the Salesforce platform, the nCino Bank Operating System connects financial institutions

Akouos, a preclinical biotech developing gene therapies for inner ear disorders, announced terms for its IPO on Monday. The Boston, MA-based company plans to raise $125 million by offering 8.3 million shares at a price range of $14 to $16. At the midpoint of the proposed range, A

PolyPid, a Phase 3 biotech developing extended-release drugs to prevent surgical site infections, announced terms for its IPO on Monday. This is PolyPid's third attempt to go public. It last filed in February 2018 but withdrew a month later, citing market conditions. The Pet

Fusion Pharmaceuticals, a Phase 1 biotech developing precision medicines for solid tumors, announced terms for its IPO on Monday. The Hamilton, Canada-based company plans to raise $125 million by offering 8.4 million shares at a price range of $14 to $16. At the midpoint of the p

Two IPOs and one SPAC are expected to raise $1.4 billion in the week ahead, led by grocery giant Albertsons (ACI). Chinese tech platform Agora (API) could price this coming week as well. Several companies could join the IPO calendar early in the week, such as PolyPid (PYPD), Fus

Five IPOs and one SPAC went public this past week led by Royalty Pharma (RPRX), which completed the largest US IPO of 2020 to date. Healthcare continued to dominate, with all five IPOs coming from the sector. Royalty Pharma (RPRX) priced its upsized at the high end to raise $2.2

InMed Pharmaceuticals, a Phase 1 developing cannabinoid-based products, filed on Friday with the SEC to raise up to $12 million in an initial public offering. The company is currently is listed on the TSX under the symbol IN and on the OTCQX under the symbol IMLFF. InMed Pharmace

Poseida Therapeutics, a Phase 2 biotech developing CAR T cell therapies for multiple myeloma, filed on Friday with the SEC to raise up to $115 million in an initial public offering. The company previously filed to raise $115 million in January 2019, but withdrew the offering afte